GlassScriptPhysician profile
Nidhi Jain
NPI 1306936877
$8,792.13
in general payments reported to CMS, 2019-2025
42 companies · $1,717 in 2025
The $1,717 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,002 · 2020: $265 · 2021: $472 · 2022: $1,466 · 2023: $1,613 · 2024: $1,258 · 2025: $1,717.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,566 · Education: $21.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,566.27 |
| Education | $21.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,134.13 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Dexcom, INC. | $846.60 | 2019-2025 | Dexcom G6 Transmitter |
| Stimwave Technologies Incorporated | $619.84 | 2019 | |
| Abbott Laboratories | $533.47 | 2019-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $502.33 | 2019-2025 | |
| Lilly USA, LLC | $501.41 | 2019-2025 | Mounjaro, Jardiance, Baqsimi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $436.84 | 2019-2025 | Jardiance, Synjardy |
| Xeris Pharmaceuticals, INC. | $426.66 | 2022-2025 | Recorlev, Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $415.49 | 2022-2025 | |
| Abbvie INC. | $388.30 | 2019-2025 | |
| Medtronic, INC. | $362.76 | 2022-2025 | Simplera Sensor, Minimed 780g |
| Insulet Corporation | $352.83 | 2019-2025 | Omnipod |
| Amgen INC. | $329.45 | 2019-2025 | Evenity, Prolia, Tepezza |
| Cequr Corporation | $254.46 | 2024-2025 | Cequr Simplicity |
| Tandem Diabetes Care, INC. | $246.35 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $196.95 | 2023-2024 | Crysvita |
| Horizon Therapeutics Plc | $107.32 | 2022-2023 | |
| Corcept Therapeutics | $104.98 | 2019-2025 | Korlym |
| Nevro Corp. | $99.69 | 2022-2024 | Senza |
| Ascendis Pharma Endocrinology INC | $88.60 | 2023-2025 | Yorvipath, Skytrofa |
| Recordati_rare_diseases_inc. | $78.63 | 2023-2025 | Isturisa, Signifor Lar |
| Novartis Pharmaceuticals Corporation | $74.56 | 2021-2025 | |
| Beta Bionics, INC. | $73.29 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Astrazeneca Pharmaceuticals LP | $71.63 | 2019-2022 | |
| Shire North American Group INC | $66.74 | 2019 | |
| Valeritas, INC. | $47.21 | 2019 | |
| Chiesi USA, INC. | $42.63 | 2024-2025 | Mycapssa |
| Ultragenyx Pharmaceutical INC. | $41.01 | 2023-2024 | Crysvita |
| Antares Pharma, INC. | $39.57 | 2022 | |
| Sequel Med Tech, LLC | $36.98 | 2025 | Twiist |
| Janssen Pharmaceuticals, INC | $36.10 | 2019 | |
| Radius Health, INC. | $32.34 | 2021 | |
| Averitas Pharma INC. | $31.05 | 2024 | Qutenza |
| Regeneron Healthcare Solutions, INC. | $30.18 | 2019 | |
| Boston Scientific Corporation | $27.67 | 2024 | Wavewriter Alpha Prime 16 |
| Becton, Dickinson and Company | $22.02 | 2022 | |
| Almatica Pharma LLC | $17.93 | 2025 | Teriparatide |
| Amarin Pharma, INC. | $17.74 | 2019 | |
| Pfizer INC. | $16.84 | 2023 | |
| Medtronic Minimed, INC. | $14.98 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.08 | 2019 | |
| Lifescan, INC. | $11.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nidhi Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.